Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
6
Expiration
Oct 23, 2026
DTE
3d
Moneyness
ITM
Intrinsic
$2.48
IBRX 6 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $4.53 | +0.00% | 1 | 1 |
| Oct 30, 2026 | 10d | — | — | 0 | 0 |
| Nov 6, 2026 | 17d | — | — | 0 | 0 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | $3.50 | -12.50% | 53 | 147 |
| Nov 27, 2026 | 38d | $3.92 | +0.00% | 2 | 2 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Mar 19, 2027 | 150d | $4.45 | -3.26% | 2 | 17 |
| Apr 16, 2027 | 178d | $3.90 | +30.00% | 1 | 0 |
| May 21, 2027 | 213d | $3.30 | +0.00% | 1 | 1 |
IBRX Nearby Strikes · Oct 23, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 3 C | $7.05 | +2.32% | 2 | 111 | ITM |
| 3.5 C | $6.49 | -0.61% | 1 | 11 | ITM |
| 4 C | $6.06 | -3.35% | 1 | 53 | ITM |
| 4.5 C | $5.90 | +8.26% | 7 | 11 | ITM |
| 5 C | $5.10 | +82.14% | 1 | 1 | ITM |
| 5.5 C | $4.27 | +55.27% | 2 | 1 | ITM |
| 6 C | $4.53 | +0.00% | 1 | 1 | ITM |
| 6.5 C | — | — | 0 | 0 | ITM |
| 7 C | $3.00 | +0.00% | 10 | 10 | ITM |
| 7.5 C | $2.47 | -14.83% | 13 | 24 | ITM |
| 8 C | $2.17 | +3.33% | 11 | 23 | ITM |
| 8.5 C | $1.82 | -4.71% | 11 | 95 | OTM |
| 9 C | $0.50 | -60.00% | 168 | 243 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.